WFDC2 and ovarian carcinoma: A number of different expression studies have clearly identified that WFDC2 is disregulated at the RNA level in ovarian cancers [13-16] and a recent study has suggested that measuring levels of WFDC2 in the serum of patients with ovarian cancer may be useful in monitoring disease progression [19].